Company Encyclopedia
View More
name
IQ Healthy Heart ETF
HART.US
News
View More

Move over D-Wave, Alphabet is taking over quantum computing

D-Wave is a promising pure play, but Alphabet's resources could position it to be a bigger quantum-computing winner.

MSN·
US
QBTS
-6.72%
US
GOOG
-1.01%
US
GOOGL
-1.01%
MSN·
US
QBTS
-6.72%
US
GOOG
-1.01%
US
GOOGL
-1.01%

November 2025 Jobs Preview: What To Expect

Job growth has slowed, averaging 40,000 jobs per month recently, compared to 170,000 in 2024, due to reduced immigration. Healthcare is the main sector adding jobs, while manufacturing and mining are losing jobs. Unemployment has risen to 4.4%, affecting disadvantaged groups more. Wage growth is weakening, with real wages barely increasing. November's unemployment rate may rise to 4.5% or higher, with voluntary quits decreasing, indicating worker insecurity.

Talkmarkets·
US
UNH
+1.52%
Talkmarkets·
US
UNH
+1.52%

Key facts: Abbott Laboratories appoints Nita Ahuja to Board; VP reports share gift

On December 12, 2025, Abbott Laboratories appointed Nita Ahuja, M.D. to its Board of Directors.1On December 12, 2025, Daniel Gesua Sive Salvadori, Vice President of Abbott Laboratories, reported a gift of 1,536 shares through a Form 4 filing, bringing his total direct holdings to 132,233 shares.2

TradingView·
US
ABT
+1.77%
TradingView·
US
ABT
+1.77%

The Nex Playground and Pixel Buds 2A top our list of the best deals this week

The Nex Playground console is on sale for $199 at Amazon, offering kid-friendly games and motion-controlled gameplay. Genki's Moonbase Charging Station is discounted to $89.99 at Amazon, featuring a retro-futuristic design and multiple charging ports. Google Pixel Buds 2A are available for $99 at Amazon, Best Buy, and Target, offering active noise cancellation and hands-free Gemini support. Additional deals include Apple's M4-powered MacBook Air 13, Hoto's PixelDrive electric screwdriver, and the Lego Super Mario Goombas' Playground set.

The Verge·
US
GOOG
-1.01%
US
GOOGL
-1.01%
The Verge·
US
GOOG
-1.01%
US
GOOGL
-1.01%

Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far?

The article evaluates Eli Lilly's stock valuation amidst its significant growth, driven by obesity and diabetes treatments. Despite a 32.1% year-to-date increase, a valuation framework scores it 1/6, indicating it's expensive by traditional metrics. A DCF analysis suggests it's undervalued by 19.4%, while a PE ratio analysis finds it overvalued. The article introduces "Narratives" for a holistic valuation approach, linking company stories to financial forecasts.

Simplywall·
US
LLY
+1.80%
Simplywall·
US
LLY
+1.80%
© 2025 Longbridge｜Disclaimer